ReviewCancer management and research2025
Efficacy of EGFR Targeting IR700-Related Photoimmunotherapy in Preventing Growth of Cancer Cells-A Systematic Review.
Review in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Research of Near-Infrared Photoimmunotherapy (NIR-PIT) related to human epidermal growth factor receptor (EGFR) in cancer is very popular in recent years. By destroying the cell membrane, NIR-PIT can kill cancer cells and prevent tumor development. By using a statistical method, our study aims to find out the suitable indices for evaluating the efficacy of EGFR-targeted NIR-PIT. Methods: Exploring strategy: (mice OR vivo study OR animal model) AND (NIR-PIT OR near-infrared photoimmunotherapy OR photoimmunotherapy) AND (EGFR OR EGFR receptor) AND (cancer OR tumor). Including standard: ① Reports could obtain full text from 2014 to 2024. ② Reports using tumor volume as an index of outcome. ③ Reports using IR-700, NIR-PIT, and EGFR antigens. The exclusion criteria were as follows: ① Reports could not obtain the full text. ② Reports that did not use the index above. ③ Reports that did not use IR-700, NIR-PIT, or EGFR antigens. ④ Reports could not obtain concrete data from articles. Results: Using the above standards, we finally acquired 20 articles that conformed to requests. In this analysis, tumor volume showed statistical meaning of differentiation between experimental and control groups. However, 50% survival did not show the statistical meaning in the analysis. Discussion: Through analysis, we found that the NIR-PIT groups had obvious differences compared with the control groups in tumor volume. However, we did not find any difference in the survival rates between NIR-PIT and control groups. This may be due to the following reasons: ① the number of samples was insufficient. ② Other indices of survival rate were more suitable in this study than 50% survival rate. Conclusion: Compared with 50% survival rate, tumor volume may be better for evaluating the efficacy of NIR-PIT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.